Show simple item record

dc.rights.licenseRestricted to current Rensselaer faculty, staff and students. Access inquiries may be directed to the Rensselaer Libraries.
dc.contributorTessier, Peter M.
dc.contributorUnderhill, Patrick T.
dc.contributorColón, Wildfredo
dc.contributor.advisorDordick, Jonathan S.
dc.contributor.authorAlam, Magfur E
dc.date.accessioned2021-12-22T20:09:29Z
dc.date.available2021-12-22T20:09:29Z
dc.date.issued2019-12
dc.identifier.urihttps://hdl.handle.net/20.500.13015/4093
dc.descriptionDecember 2019
dc.descriptionSchool of Engineering
dc.description.abstractThere has been an explosion in the development of therapeutic monoclonal antibodies (mAbs) in recent years due to their high affinities, specificities, stabilities and other drug-like properties. The development of antibody therapeutics, however, is a long, arduous and complicated process. The overall goal of this research is to address several key fundamental challenges related to generating and formulating antibodies for therapeutic applications. First, antibodies are commonly affinity maturated in vitro using monovalent antibody fragments (Fabs) prior to reformatting them as bivalent mAbs for therapeutic applications. A common problem is that engineered Fabs display poor biophysical properties (e.g., low solubility or high viscosity) when reformatted as bivalent antibodies. Therefore, we have sought to develop methods for profiling the biophysical properties of monovalent antibody fragments in a manner that is predictive of their properties as bivalent antibodies prior to reformatting. We have developed a nanoparticle-based assay (self-interaction nanoparticle spectroscopy, SINS) to measure Fab self-association in a multivalent format with the goal of sampling colloidal interactions that are similar to those for bivalent mAbs. Moreover, we have extended these biophysical studies to evaluate the effects of chemical modifications (e.g., deamidation and oxidation) on the aggregation behavior of mAbs. In particular, we have investigated how chemical modifications of antibodies lead to aggregation during challenging downstream processing conditions (e.g., low pH). Interestingly, we find little correlation between the impact of these chemical modifications on antibody conformational stability and aggregation. Methionine oxidation leads to significant reductions in antibody conformational stability while having little impact on antibody aggregation except at extreme conditions (low pH and elevated temperature). Conversely, tryptophan oxidation and asparagine deamidation have little impact on antibody conformational stability while promoting aggregation at a wide range of solution conditions, and the aggregation mechanisms appear linked to unique types of reducible and non-reducible covalent crosslinks and, in some cases, to increased levels of attractive colloidal interactions. We expect that our findings will improve the generation of safe and potent antibody therapeutics.
dc.languageENG
dc.language.isoen_US
dc.publisherRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofRensselaer Theses and Dissertations Online Collection
dc.subjectChemical engineering
dc.titleBiophysical and bioinformatics analysis of antibody colloidal and conformational stabilityen_US
dc.typeElectronic thesis
dc.rights.holderThis electronic version is a licensed copy owned by Rensselaer Polytechnic Institute, Troy, NY. Copyright of original work retained by author.
dc.identifier.oclc1313562057
dc.description.degreePhD
dc.relation.departmentDept. of Chemical and Biological Engineering


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record